Jilin Province Huinan Changlong Bio-pharmacy Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Jilin Province Huinan Changlong Bio-pharmacy.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth	10.9%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	None
Last updated	n/a

Recent future growth updates

No updates

Recent updates

Here's Why Shareholders May Consider Paying Jilin Province Huinan Changlong Bio-pharmacy Company Limited's (HKG:8049) CEO A Little More

May 21

There May Be Reason For Hope In Jilin Province Huinan Changlong Bio-pharmacy's (HKG:8049) Disappointing Earnings

Apr 04

With EPS Growth And More, Jilin Province Huinan Changlong Bio-pharmacy (HKG:8049) Makes An Interesting Case

Mar 26

Investors Don't See Light At End Of Jilin Province Huinan Changlong Bio-pharmacy Company Limited's (HKG:8049) Tunnel

Dec 27

With EPS Growth And More, Jilin Province Huinan Changlong Bio-pharmacy (HKG:8049) Makes An Interesting Case

Jul 12

It's Unlikely That Shareholders Will Increase Jilin Province Huinan Changlong Bio-pharmacy Company Limited's (HKG:8049) Compensation By Much This Year

Jun 05

How Is Jilin Province Huinan Changlong Bio-pharmacy's (HKG:8049) CEO Paid Relative To Peers?

Nov 26

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Jilin Province Huinan Changlong Bio-pharmacy has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

SEHK:8049 - Analysts future estimates and past financials data (CNY Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
6/30/2024	839	172	N/A	N/A	N/A
3/31/2024	896	148	N/A	N/A	N/A
12/31/2023	842	148	284	316	N/A
9/30/2023	841	222	N/A	N/A	N/A
6/30/2023	860	197	N/A	N/A	N/A
3/31/2023	791	212	N/A	N/A	N/A
12/31/2022	842	194	193	204	N/A
9/30/2022	825	151	N/A	N/A	N/A
6/30/2022	781	172	N/A	N/A	N/A
3/31/2022	750	157	N/A	N/A	N/A
12/31/2021	705	143	122	215	N/A
9/30/2021	655	141	N/A	N/A	N/A
6/30/2021	638	124	N/A	N/A	N/A
3/31/2021	641	133	N/A	N/A	N/A
12/31/2020	622	127	52	151	N/A
9/30/2020	614	140	N/A	N/A	N/A
6/30/2020	632	143	N/A	N/A	N/A
3/31/2020	635	143	N/A	N/A	N/A
12/31/2019	646	145	115	133	N/A
9/30/2019	637	157	N/A	N/A	N/A
6/30/2019	635	159	193	227	N/A
3/31/2019	628	158	N/A	N/A	N/A
12/31/2018	648	161	105	139	N/A
9/30/2018	646	144	N/A	N/A	N/A
6/30/2018	648	144	10	46	N/A
3/31/2018	653	145	N/A	N/A	N/A
12/31/2017	645	144	N/A	147	N/A
9/30/2017	663	146	N/A	N/A	N/A
6/30/2017	667	145	N/A	151	N/A
3/31/2017	658	144	N/A	N/A	N/A
12/31/2016	654	143	N/A	124	N/A
9/30/2016	614	125	N/A	N/A	N/A
6/30/2016	572	116	N/A	140	N/A
3/31/2016	567	120	N/A	N/A	N/A
12/31/2015	539	118	N/A	152	N/A
9/30/2015	623	138	N/A	N/A	N/A
6/30/2015	624	138	N/A	54	N/A
3/31/2015	616	135	N/A	N/A	N/A
12/31/2014	602	133	N/A	49	N/A
9/30/2014	518	91	N/A	N/A	N/A
6/30/2014	487	85	N/A	113	N/A
3/31/2014	466	81	N/A	N/A	N/A
12/31/2013	458	79	N/A	83	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if 8049's forecast earnings growth is above the savings rate (2.3%).

Earnings vs Market: Insufficient data to determine if 8049's earnings are forecast to grow faster than the Hong Kong market

High Growth Earnings: Insufficient data to determine if 8049's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if 8049's revenue is forecast to grow faster than the Hong Kong market.

High Growth Revenue: Insufficient data to determine if 8049's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 8049's Return on Equity is forecast to be high in 3 years time

Jilin Province Huinan Changlong Bio-pharmacy Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Recent updates

Investor sentiment improves as stock rises 15%

First half 2024 earnings released: EPS: CN¥0.19 (vs CN¥0.14 in 1H 2023)

Jilin Province Huinan Changlong Bio-pharmacy Company Limited to Report First Half, 2024 Results on Aug 14, 2024

New minor risk - Market cap size

Upcoming dividend of HK$0.069 per share

Jilin Province Huinan Changlong Bio-Pharmacy Company Limited Approves Special Dividend, Payable on or Before 16 July 2024

Here's Why Shareholders May Consider Paying Jilin Province Huinan Changlong Bio-pharmacy Company Limited's (HKG:8049) CEO A Little More

Jilin Province Huinan Changlong Bio-Pharmacy Company Limited Proposes Special Dividend, to Be Payable on or Before 16 July 2024

Jilin Province Huinan Changlong Bio-Pharmacy Company Limited Proposes Special Dividend, to Be Payable on or Before 16 July 2024

Jilin Province Huinan Changlong Bio-pharmacy Company Limited, Annual General Meeting, May 28, 2024

Investor sentiment improves as stock rises 17%

There May Be Reason For Hope In Jilin Province Huinan Changlong Bio-pharmacy's (HKG:8049) Disappointing Earnings

Full year 2023 earnings released

With EPS Growth And More, Jilin Province Huinan Changlong Bio-pharmacy (HKG:8049) Makes An Interesting Case

Investors Don't See Light At End Of Jilin Province Huinan Changlong Bio-pharmacy Company Limited's (HKG:8049) Tunnel

Investor sentiment improves as stock rises 15%

Third quarter 2023 earnings released: EPS: CN¥0.094 (vs CN¥0.049 in 3Q 2022)

Jilin Province Huinan Changlong Bio-pharmacy Company Limited to Report Q3, 2023 Results on Nov 14, 2023

Second quarter 2023 earnings released: EPS: CN¥0.051 (vs CN¥0.078 in 2Q 2022)

Jilin Province Huinan Changlong Bio-pharmacy Company Limited to Report First Half, 2023 Results on Aug 14, 2023

With EPS Growth And More, Jilin Province Huinan Changlong Bio-pharmacy (HKG:8049) Makes An Interesting Case

New minor risk - Market cap size

Investor sentiment improves as stock rises 20%

Jilin Province Huinan Changlong Bio-Pharmacy Company Limited Approves Special Dividend, Payment Date 30 June 2023

Upcoming dividend of CN¥0.50 per share at 33% yield

Full year 2022 earnings released: EPS: CN¥0.34 (vs CN¥0.26 in FY 2021)

Investor sentiment improves as stock rises 17%

Third quarter 2022 earnings released: EPS: CN¥4.89 (vs CN¥0.086 in 3Q 2021)

Less than half of directors are independent

Jilin Province Huinan Changlong Bio-pharmacy Company Limited to Report Nine Months, 2022 Results on Nov 14, 2022

Second quarter 2022 earnings released: EPS: CN¥0.078 (vs CN¥0.052 in 2Q 2021)

Jilin Province Huinan Changlong Bio-pharmacy Company Limited to Report First Half, 2022 Results on Aug 12, 2022

Upcoming dividend of HK$0.073 per share

Jilin Province Huinan Changlong Bio-Pharmacy Company Limited Approves Special Dividend, Payable on or Before 31 August 2022

First quarter 2022 earnings released: EPS: CN¥0.06 (vs CN¥0.036 in 1Q 2021)

Jilin Province Huinan Changlong Bio-Pharmacy Company Limited Proposes Special Divided, Payable on or Before 31 August 2022

Jilin Province Huinan Changlong Bio-Pharmacy Company Limited Proposes Special Divided, Payable on or Before 31 August 2022

Less than half of directors are independent

Jilin Province Huinan Changlong Bio-pharmacy Company Limited to Report Fiscal Year 2021 Results on Apr 29, 2022

Full year 2021 earnings released

Jilin Province Huinan Changlong Bio-pharmacy Company Limited to Report Fiscal Year 2021 Results on Mar 31, 2022

Third quarter 2021 earnings released

Upcoming dividend of CN¥0.028 per share

Jilin Province Huinan Changlong Bio-Pharmacy Company Limited Announces Special Dividend , Payable on November 18, 2021

Independent Non-Executive Director Yong Cai Gao has left the company

Jilin Province Huinan Changlong Bio-Pharmacy Company Limited Proposes Special Dividend

Second quarter 2021 earnings released: EPS CN¥0.052 (vs CN¥0.067 in 2Q 2020)

Jilin Province Huinan Changlong Bio-Pharmacy Company Limited Recommends Special Dividend, Payable on or Before November 18, 2021

Upcoming dividend of CN¥0.035 per share

Jilin Province Huinan Changlong Bio-pharmacy Company Limited Approves Special Dividend, Payable on or Before August 30, 2021

It's Unlikely That Shareholders Will Increase Jilin Province Huinan Changlong Bio-pharmacy Company Limited's (HKG:8049) Compensation By Much This Year

First quarter 2021 earnings released: EPS CN¥0.036 (vs CN¥0.025 in 1Q 2020)

Jilin Province Huinan Changlong Bio-Pharmacy Company Limited Proposes Special Dividend, Payable on or Before August 30, 2021

Full year 2020 earnings released: EPS CN¥0.23 (vs CN¥0.26 in FY 2019)

Jilin Province Huinan Changlong Bio-pharmacy Company Limited to Report Fiscal Year 2020 Results on Mar 31, 2021

New 90-day low: HK$1.12

New 90-day low: HK$1.17

New 90-day low: HK$1.29

How Is Jilin Province Huinan Changlong Bio-pharmacy's (HKG:8049) CEO Paid Relative To Peers?

New 90-day low: HK$1.30

Third quarter 2020 earnings released: EPS CN¥0.056

Jilin Province Huinan Changlong Bio-pharmacy Company Limited to Report Q3, 2020 Results on Nov 13, 2020

First half earnings released

Jilin Province Huinan Changlong Bio-pharmacy Company Limited to Report First Half, 2020 Results on Aug 14, 2020

New 90-day low - HK$1.29

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies